Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel Advanced Development of Multivalent Filovirus (Ebola and Marburg) Hemorrhagic Fever Vaccines.
Date: March 20, 2008.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate contract proposals.
Place: Crowne Plaza Washington DC Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.
Contact Person: Lynn Rust, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892, (301) 402-3938, firstname.lastname@example.org. Start Printed Page 13007
This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)Start Signature
Dated: March 3, 2008.
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E8-4564 Filed 3-10-08; 8:45 am]
BILLING CODE 4140-01-M